Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products
| | | | | | |

Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products

On Jul. 2, 2024, Emergent BioSolutions announced it had received more than $250 millionin contract modifications from the…

USDA Approved Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
| | | | | |

USDA Approved Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza

On Jun. 25, 2024, Merck Animal Health announced U.S. Department of Agriculture (USDA) approval of NOBIVAC® NXT Canine…